SCHEMBL5326756

SCHEMBL5326756

NS(=O)(=O)NCCCCCC(=O)Nc1nc(-c2ccccc2)c(-c2ccccc2)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 9/20 0.66
HDAC3 O15379 2/20 0.60
HDAC1 Q13547 2/20 0.60
HDAC4 P56524 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60
RORC P51449 1/20 0.53
XIAP P98170 3/20 0.50
PTGS2 P35354 1/20 0.48
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5327135 0.81 RORC (0.47) HDAC6HDAC3HDAC1HDAC4HDAC7
SCHEMBL5455223 0.81 HDAC6 (0.78) HDAC6HDAC3HDAC1HDAC4HDAC7
SCHEMBL10254354 0.81 PTGS2 (0.61) RORCXIAPPTGS2ALDH1A1KDM4E
SCHEMBL5326834 0.80 HDAC6 (1.00) HDAC6HDAC3HDAC1HDAC4HDAC7
SCHEMBL18015884 0.78 PTGS2 (0.55) RORCXIAPPTGS2ALDH1A1KDM4E
SCHEMBL31203337 0.78 HDAC8 (0.68) HDAC6HDAC3HDAC1HDAC4HDAC7
SCHEMBL31203398 0.78 CYP3A4 (0.48) HDAC6HDAC3HDAC1HDAC4HDAC7
SCHEMBL2752606 0.77 ALDH1A1 (0.74) RORCXIAPPTGS2ALDH1A1KDM4E
SCHEMBL8115630 0.75 HDAC6 (1.00) HDAC6HDAC3HDAC1HDAC4HDAC7
SCHEMBL5326902 0.75 HDAC6 (1.00) HDAC6HDAC3HDAC1HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007143822-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-21 WO disclosed
WO-2007143822-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-21 WO disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 HDAC6 11/4885HDAC3 4/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.